Related Experiment Video
Updated: Jun 21, 2025
In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
Published on: February 16, 2016
Volatilome: A Novel Tool for Risk Scoring in Ischemic Heart Disease
1World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, 119991, Russia.
Insights
Developing a new cardiovascular disease (CVD) risk score is crucial. This study proposes incorporating exhaled volatile organic compounds as a novel non-classical risk factor to improve predictions for ischemic heart disease.
Area of Science:
- Cardiology
- Biomarkers
- Preventive Medicine
Background:
- Accurate cardiovascular disease (CVD) risk assessment is vital for prevention and management, especially for ischemic heart disease.
- Current risk scores using classical factors have limitations in predictive accuracy.
- There is an urgent need for improved CVD risk stratification tools.
Purpose of the Study:
- To propose a novel risk score for cardiovascular disease (CVD) morbidity and mortality.
- To enhance existing risk algorithms like SCORE2 and SCORE2-OP.
- To integrate non-classical risk factors into CVD risk prediction models.
Main Methods:
- Suggesting the addition of exhaled volatile organic compounds (VOCs) as a novel non-classical risk factor.
- Combining these VOCs with established classical risk factors (e.g., cholesterol, blood pressure, diabetes, smoking).
- Developing a new algorithm and a program for widespread clinical application.
Main Results:
- The study proposes a novel approach to CVD risk assessment.
- Incorporating exhaled VOCs is suggested to improve the accuracy of risk scores.
- The proposed method aims to enhance the predictive value of existing algorithms like SCORE2 and SCORE2-OP.
Conclusions:
- Novel non-classical risk factors, such as exhaled volatile organic compounds, can significantly improve cardiovascular disease risk prediction.
- Integrating these biomarkers into algorithms like SCORE2 and SCORE2-OP offers a promising avenue for more accurate ischemic heart disease assessment.
- The development of a new, widely applicable algorithm incorporating these factors is recommended for clinical practice.
Abstract:
Developing a novel risk score for accurate assessment of cardiovascular disease (CVD) morbidity and mortality is an urgent need in terms of early prevention and diagnosis and, thereafter, management, particularly of ischemic heart disease. The currently used scores for the evaluation of cardiovascular disease based on the classical risk factors suffer from severe limitations, including inaccurate predictive values. Therefore, we suggest adding a novel non-classical risk factor, including the level of specific exhaled volatile organic compounds that are associated with ischemic heart disease, to the SCORE2 and SCORE2-OP algorithms. Adding these nonclassical risk factors can be used together with the classical risk factors (gender, smoking, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, diabetes mellitus, arterial hypertension, ethnicity, etc.) to develop a new algorithm and further program to be used widely.
